Protective effects of rimeporide on left ventricular function in golden retriever muscular dystrophy dogs.

Research paper by Bijan B Ghaleh, Inès I Barthélemy, Jérôme J Wojcik, Lucien L Sambin, Alain A Bizé, Luc L Hittinger, Thien Duc TD Tran, Florence Porte FP Thomé, Stéphane S Blot, Jin Bo JB Su

Indexed on: 23 Mar '20Published on: 23 Mar '20Published in: International Journal of Cardiology


Alterations in intracellular Na and Ca have been observed in patients with Duchenne muscular dystrophy (DMD) and in animal models of DMD, and inhibition of Na-H exchanger 1 (NHE1) by rimeporide has previously demonstrated cardioprotective effects in animal models of myocardial ischemia and heart failure. Since heart failure is becoming a predominant cause of death in DMD patients, this study aimed to demonstrate a cardioprotective effect of chronic administration of rimeporide in a canine model of DMD. Golden retriever muscular dystrophy (GRMD) dogs were randomized to orally receive rimeporide (10 mg/kg, twice a day) or placebo from 2 months to 1 year of age. Left ventricular (LV) function was assessed by conventional and advanced echocardiography. Compared with placebo-treated GRMD, LV function deterioration with age was limited in rimeporide-treated GRMD dogs as indicated by the preservation of LV ejection fraction as well as overall cardiac parameters different from placebo-treated dogs, as revealed by composite cardiac scores and principal component analysis. In addition, principal component analysis clustered rimeporide-treated GRMD dogs close to healthy control dogs. Chronic administration of the NHE1 inhibitor rimeporide exerted a protective effect against LV function decline in GRMD dogs. This study provides proof of concept to explore the cardiac effects of rimeporide in DMD patients. Copyright © 2020 Elsevier B.V. All rights reserved.

More like this: